Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income	$ 36,741	$ 30,259	$ 18,143
Adjustments to reconcile to net cash provided by operating activities:
Stock-based compensation expense	12,829	11,238	11,115
Other Depreciation and Amortization	32,453	18,958	11,197
Deferred income taxes	16,493	13,858	3,383
Non-cash development expenses from joint venture	0	(347)	3,670
Change in fair value of contingent obligations	3,133	735	(3,005)
Write off of debt issuance costs	1,831	0	0
Impairment of in-process research and development	0	0	9,600
Impairment of long-lived assets	0	1,172	0
Excess tax benefits from stock-based compensation	(5,987)	(3,099)	(1,588)
Other	1,284	51	(40)
Changes in operating assets and liabilities:
Accounts receivable	21,405	35,456	(21,890)
Inventories	4,229	518	(500)
Income taxes	(4,711)	(7,179)	8,055
Prepaid expenses and other assets	(8,472)	(6,226)	(1,038)
Accounts payable	(9,279)	(551)	274
Accrued expenses and other liabilities	2,685	7	169
Accrued compensation	4,539	2,092	1,649
Provision for chargebacks	299	0	0
Deferred revenue	2,846	26	449
Net cash provided by operating activities	112,318	96,968	39,643
Cash flows from investing activities:
Purchases of property, plant and equipment	(30,673)	(42,021)	(53,845)
Proceeds from sale of assets	0	0	11,765
Proceeds from maturity of investments	0	0	1,966
Acquisition of Healthcare Protective Products Division	(179,379)	(25,873)	0
Net cash used in investing activities	(210,052)	(67,894)	(40,114)
Cash flows from financing activities:
Proceeds from convertible debenture, net of debt issuance costs	241,588	0	0
Proceeds from borrowings on long-term indebtedness	1,000	62,000	13,547
Issuance of common stock subject to employee equity plans	14,078	6,848	761
Excess tax benefits from stock-based compensation	5,987	3,099	1,588
Principal payments on long-term indebtedness and line of credit	(62,000)	(62,774)	(10,227)
Contingent obligation payments	(1,579)	(348)	(1,748)
Purchase of treasury stock	(200)	(213)	(5,906)
Restricted cash deposit	0	0	220
Net cash provided by (used in) financing activities	198,874	8,612	(1,765)
Effect of exchange rate changes on cash and cash equivalents	21	(14)	1
Net increase (decrease) in cash and cash equivalents	101,161	37,672	(2,235)
Cash and cash equivalents at beginning of year	179,338	141,666	143,901
Cash and cash equivalents at end of year	280,499	179,338	141,666
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	3,761	2,055	2,137
Cash paid during the year for income taxes	4,711	6,331	6,537
Supplemental information on non-cash investing and financing activities:
Purchases of property, plant and equipment unpaid at year end	$ 5,394	$ 2,755	$ 5,612